P1.02. Co-inhibition of MEK/RTKs Pathways via Trametinib Plus Anlotinib forKRAS-Mutant NSCLC - PDF(Slides)
Back to course
Pdf Summary
Asset Subtitle
Baohui Han
Meta Tag
Speaker Baohui Han
Topic Tumor Biology: Preclinical Biology - Molecular Therapeutic Targets
Keywords
KRAS-mutant non-small cell lung cancer
therapeutic strategy
KRAS mutation
NSCLC
KRAS mutation subtypes
functional analysis
mechanism analysis
multi-omics analysis
signaling pathways
anti-tumor efficacy
Powered By